9 recruiting, 2 not yet recruiting, 1 unknown. 6 Phase 1, 3 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 4, Not yet recruiting 2 |
| Early Phase 1 | 3 | Recruiting 2, Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow CAR-T Therapy: new trials by email Literature Review of CAR-T Therapy trials Research Report on CAR-T Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus CAR-T Therapy - Systemic Lupus Erythematosus (SLE) | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-01-16 | 2026-01-14 |
| Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC CAR-T Therapy - SSc-Systemic Sclerosis | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-01-16 | 2026-01-21 |
| To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT CAR-T Therapy - CD7+ T-ALL/LBL | Phase 1 | Recruiting | Peking University People's Hospital | 18 | 2025-08-18 | 2025-12-12 |
| Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody - Multiple Myeloma, Relapsed, Multiple Myeloma (MM) | Recruiting | Sung-Soo Park | 174 | 2025-07-14 | 2025-07-15 | |
| Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE CAR-T Therapy - Systemic Lupus Erythematosus (SLE) | Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2025-07-11 | 2025-11-24 |
| The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis CAR-T Therapy - ANCA Associated Vasculitis (AAV) | Phase 1 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2025-07-01 | 2025-06-24 |
| CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc) CAR-T Therapy - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Recruiting | Beijing GoBroad Hospital | 27 | 2025-02-20 | 2026-03-10 |
| CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors CAR-T Therapy - CAR-T Cell Therapy, Lymphomas | Phase 1 | Not yet recruiting | Mingzhi Zhang | 30 | 2024-12-01 | 2024-10-17 |
| CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. CAR-T Therapy - Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Guangzhou Women and Children's Medical Center | 10 | 2024-10-01 | 2024-12-31 |
| Immunotherapy in Lymphoma CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate - Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma | Recruiting | Sung-Soo Park | 72 | 2024-06-26 | 2025-01-28 | |
| Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. Fecal Microbiota Transplantation, Chemotherapy, CAR-T Therapy - Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-02-19 | 2026-11-12 |
| Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma CAR-T Therapy - Peripheral T Cell Lymphoma | Early Phase 1 | Unknown | Zhao Weili | 35 | 2023-09-01 | 2023-08-21 |
Lupus Erythematosus, Systemic (3) · Lymphoma (3) · Recurrence (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Burkitt Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Myeloma (1) · Neoplasm, Residual (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Scleroderma, Systemic (1)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (4) · Sung-Soo Park (2) · Beijing GoBroad Hospital (1) · Guangzhou Women and Children's Medical Center (1) · M.D. Anderson Cancer Center (1) · Mingzhi Zhang (1) · Peking University People's Hospital (1) · Zhao Weili (1)
China (9) · South Korea (2) · United States (1)
Hua Jiang, phd (1) · Neeraj Saini, MD (1) · Xiaojun Huang (1)